Retroviral vectors: Post entry events and genomic alterations

Viruses

Volumn 3, Issue 5, 2011, Pages 429-455

  Nowrouzi, Ali ^a   Glimm, Hanno ^a   von Kalle, Christof ^a   Schmidt, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Common insertion sites; Gene therapy; Insertional mutagenesis; Leukemia; Retroviral integration; Retroviral vectors; Vector genotoxicity

Indexed keywords

ARF PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P57; RETROVIRUS VECTOR; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; BASE PAIRING; BIOSAFETY; CD34 SELECTION; CELL FATE; CELL NUCLEUS; CELL TRANSPORT; CPG ISLAND; DNA STRAND; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENOTOXICITY; HEMATOPOIESIS; HUMAN; LONG TERMINAL REPEAT; MALIGNANT TRANSFORMATION; NONHUMAN; PLURIPOTENT STEM CELL; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; PYROSEQUENCING; RETROVIRUS; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SOMATIC GENE THERAPY; SPUMA VIRUS; TRANSCRIPTION INITIATION SITE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENETICS; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; DISEASE; GENE THERAPY; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; RETROVIRIDAE; VIRUS INTEGRATION; VIRUS INTERNALIZATION;

EID: 79957858127     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3050429     Document Type: Review

References (165)

1. Vogt, P.K. Historical introduction to the general properties of retroviruses. In Retroviruses; Coffin, J.M., Hughes, S.H., Varmus, E.H., Eds.; ColdSpring Harbor Laboratory Press: Cold Spring harbor, New York, NY, USA, 1997.
2. Brown, P.O. Integration. In Retroviruses; Coffin, J.M., Hughes, S.H., Varmus, E.H., Eds.; ColdSpring Harbor Laboratory Press: Cold Spring harbor, New York, NY, USA, 1997.
3. Eglitis, M.A.; Kantoff, P.; Gilboa, E.; Anderson, W.F. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 1985, 230, 1395-1398.
4. Dick, J.E.; Magli, M.C.; Huszar, D.; Phillips, R.A.; Bernstein, A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 1985, 42, 71-79.
5. Williams, D.A.; Lemischka, I.R.; Nathan, D.G.; Mulligan, R.C. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 1984, 310, 476-80.
6. Mann, R.; Mulligan, R.C.; Baltimore, D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983, 33, 153-159.
7. Miller, A.D. Development and applications of retroviral vectors. In Retroviruses; Coffin, J.M., Hughes, S.H., Varmus, E.H., Eds.; ColdSpring Harbor Laboratory Press: Cold Spring harbor, New York, NY, USA, 1997.
8. Anderson, W.F. Prospects for human gene therapy. Science 1984, 226, 401-409.
9. Suzuki, Y.; Craigie, R. The road to chromatin - nuclear entry of retroviruses. Nat. Rev. Microbiol. 2007, 5, 187-196.
10. Turlure, F.; Devroe, E.; Silver, P.A.; Engelman, A. Human cell proteins and human immunodeficiency virus DNA integration. Front. Biosci. 2004, 9, 3187-3208.
11. Edelstein, M.L.; Abedi, M.R.; Wixon, J. Gene therapy clinical trials worldwide to 2007-An update. J. Gene Med. 2007, 9, 833-842.
12. Verma, I.M.; Weitzman, M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 2005, 74, 711-738.
13. von Kalle, C.; Fehse, B.; Layh-Schmitt, G.; Schmidt, M.; Kelly, P.; Baum, C. Stem cell clonality and genotoxicity in hematopoietic cells: Gene activation side effects should be avoidable. Semin. Hematol. 2004, 41, 303-318.
14. Trobridge, G.D.; Miller, D.G.; Jacobs, M.A.; Allen, J.M.; Kiem, H.P.; Kaul, R.; Russell, D.W. Foamy virus vector integration sites in normal human cells. Proc. Nat. Acad. Sci. U. S. A. 2006, 103, 1498-1503.
15. Nowrouzi, A.; Dittrich, M.; Klanke, C.; Heinkelein, M.; Rammling, M.; Dandekar, T.; von Kalle, C.; Rethwilm, A. Genome-wide mapping of foamy virus vector integrations into a human cell line. J. Gen. Virol. 2006, 87, 1339-1347.
16. Hacker, C.V.; Vink, C.A.; Wardell, T.W.; Lee, S.; Treasure, P.; Kingsman, S.M.; Mitrophanous, K.A.; Miskin, J.E. The integration profile of EIAV-based vectors. Mol. Ther. 2006, 14, 536-545.
17. Narezkina, A.; Taganov, K.D.; Litwin, S.; Stoyanova, R.; Hayashi, J.; Seeger, C.; Skalka, A.M.; Katz, R.A. Genome-wide analyses of avian sarcoma virus integration sites. J. Virol. 2004, 78, 11656-11663.
18. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004, 2, E234.
19. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300, 1749-1751.
20. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521-529.
21. Bushman, F.; Lewinski, M.; Ciuffi, A.; Barr, S.; Leipzig, J.; Hannenhalli, S.; Hoffmann, C. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 2005, 3, 848-858.
22. Nienhuis, A.W.; Dunbar, C.E.; Sorrentino, B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 2006, 13, 1031-1049.
23. Temin, H.M.; Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970, 226, 1211-1213.
24. Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970, 226, 1209-1211.
25. Temin, H.M. The DNA provirus hypothesis. Science 1976, 192, 1075-1080.
26. Temin, H.M. The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J. Nat. Canc. Ins. 1971, 46, 3-7.
27. Temin, H.M. Origin of retroviruses from cellular moveable genetic elements. Cell 1980, 21, 599-600.
28. Cohen, J.C.; Shank, P.R.; Morris, V.L.; Cardiff, R.; Varmus, H.E. Integration of the DNA of mouse mammary tumor virus in virus-infected normal and neoplastic tissue of the mouse. Cell 1979, 16, 333-345.
29. Steffen, D.; Weinberg, R.A. The integrated genome of murine leukemia virus. Cell 1978, 15, 1003-1010.
30. Shank, P.R.; Hughes, S.H.; Kung, H.J.; Majors, J.E.; Quintrell, N.; Guntaka, R.V.; Bishop, J.M.; Varmus, H.E. Mapping unintegrated avian sarcoma virus DNA: termini of linear DNA bear 300 nucleotides present once or twice in two species of circular DNA. Cell 1978, 15, 1383-1395.
31. Hughes, S.H.; Shank, P.R.; Spector, D.H.; Kung, H.J.; Bishop, J.M.; Varmus, H.E.; Vogt, P.K.; Breitman, M.L. Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. Cell 1978, 15, 1397-1410.
32. Battula, N.; Temin, H.M. Sites of integration of infectious DNA of avian reticuloendotheliosis viruses in different avian cellular DNAs. Cell 1978, 13, 387-398.
33. Moebes, A.; Enssle, J.; Bieniasz, P.D.; Heinkelein, M.; Lindemann, D.; Bock, M.; McClure, M. O.; Rethwilm, A. Human foamy virus reverse transcription that occurs late in the viral replication cycle. J. Virol. 1997, 71, 7305-7311.
34. Rethwilm, A. The replication strategy of foamy viruses. Curr. Topics Microbiol. Immunol. 2003, 277, 1-26.
35. Telesnitsky, A.; Goff, S.P. Reverse transkriptase and the generation of retroviral DNA. In Retroviruses; Coffin, J.M., Hughes, S. H., Varmus, E. H., Eds.; ColdSpring Harbor Laboratory Press: Cold Spring harbor, New York, NY, USA, 1997.
36. Bowerman, B.; Brown, P.O.; Bishop, J.M.; Varmus, H.E. A nucleoprotein complex mediates the integration of retroviral DNA. Gene. Develop. 1989, 3, 469-478.
37. Fujiwara, T.; Mizuuchi, K. Retroviral DNA integration: structure of an integration intermediate. Cell 1988, 54, 497-504.
38. Brown, P.O.; Bowerman, B.; Varmus, H.E.; Bishop, J.M. Correct integration of retroviral DNA in vitro. Cell 1987, 49, 347-356.
39. Petit, C.; Giron, M.L.; Tobaly-Tapiero, J.; Bittoun, P.; Real, E.; Jacob, Y.; Tordo, N.; De The, H.; Saib, A. Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J. Cell Sci. 2003, 116, 3433-3442.
40. McDonald, D.; Vodicka, M.A.; Lucero, G.; Svitkina, T.M.; Borisy, G.G.; Emerman, M.; Hope, T.J. Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 2002, 159, 441-452.
41. Saib, A.; Puvion-Dutilleul, F.; Schmid, M.; Peries, J.; de The, H. Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J. Virol. 1997, 71, 1155-1161.
42. Roe, T.; Reynolds, T.C.; Yu, G.; Brown, P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993, 12, 2099-2108.
43. Naldini, L.; Blomer, U.; Gallay, P.; Ory, D.; Mulligan, R.; Gage, F.H.; Verma, I.M.; Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272, 263-267.
44. Bushman, F.D. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 2003, 115, 135-138.
45. Craigie, R.; Fujiwara, T.; Bushman, F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 1990, 62, 829-837.
46. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 232-236.
47. Maertens, G.N.; Hare, S.; Cherepanov, P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010, 468, 326-329.
48. Katzman, M.; Mack, J.P.; Skalka, A.M.; Leis, J. A covalent complex between retroviral integrase and nicked substrate DNA. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 4695-1699.
49. Engelman, A.; Mizuuchi, K.; Craigie, R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991, 67, 1211-1221.
50. Bushman, F.D.; Fujiwara, T.; Craigie, R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990, 249, 1555-1558.
51. Yoder, K.E.; Bushman, F.D. Repair of gaps in retroviral DNA integration intermediates. J. Virol. 2000, 74, 11191-1200.
52. Holman, A.G.; Coffin, J.M. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 6103-6107.
53. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M.; Munroe, D.J. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J. Virol. 2005, 79, 5211-5214.
54. Pryciak, P.M.; Sil, A.; Varmus, H.E. Retroviral integration into minichromosomes in vitro. EMBO J. 1992, 11, 291-303.
55. Pryciak, P.M.; Varmus, H.E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell 1992, 69, 769-780.
56. Muller, H.P.; Varmus, H.E. DNA bending creates favored sites for retroviral integration: an explanation for preferred insertion sites in nucleosomes. EMBO J. 1994, 13, 4704-4714.
57. Pruss, D.; Reeves, R.; Bushman, F.D.; Wolffe, A.P. The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J. Biol. Chem. 1994, 269, 25031-25041.
58. Scherdin, U.; Rhodes, K.; Breindl, M. Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 1990, 64, 907-912.
59. Mooslehner, K.; Karls, U.; Harbers, K. Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J. Virol. 1990, 64, 3056-3058.
60. Rohdewohld, H.; Weiher, H.; Reik, W.; Jaenisch, R.; Breindl, M. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J. Virol. 1987, 61, 336-343.
61. Vijaya, S.; Steffen, D.L.; Robinson, H.L. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 1986, 60, 683-692.
62. Hacein-Bey-Abina, S.; Le Deist, F.; Carlier, F.; Bouneaud, C.; Hue, C.; De Villartay, J.P.; Thrasher, A.J.; Wulffraat, N.; Sorensen, R.; Dupuis-Girod, S.; et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002, 346, 1185-1193.
63. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M.; et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255-256.
64. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415-419.
65. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K.; et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118, 3132-3142.
66. Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D.; et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118, 3143-3150.
67. Hematti, P.; Hong, B.K.; Ferguson, C.; Adler, R.; Hanawa, H.; Sellers, S.; Holt, I.E.; Eckfeldt, C.E.; Sharma, Y.; Schmidt, M.; et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004, 2, e423.
68. Themis, M.; Waddington, S.N.; Schmidt, M.; von Kalle, C.; Wang, Y.; Al-Allaf, F.; Gregory, L.G.; Nivsarkar, M.; Themis, M.; Holder, M.V.; et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 2005, 12, 763-771.
69. Lewinski, M.K.; Yamashita, M.; Emerman, M.; Ciuffi, A.; Marshall, H.; Crawford, G.; Collins, F.; Shinn, P.; Leipzig, J.; Hannenhalli, S.; J. Virol. Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS Pathog. 2006, 2, e60.
70. Engelman, A.; Cherepanov, P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008, 4, e1000046.
71. Vandekerckhove, L.; Christ, F.; Van Maele, B.; De Rijck, J.; Gijsbers, R.; Van den Haute, C.; Witvrouw, M.; Debyser, Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol. 2006, 80, 1886-1896.
72. Llano, M.; Delgado, S.; Vanegas, M.; Poeschla, E.M. Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem. 2004, 279, 55570-55577.
73. Busschots, K.; Vercammen, J.; Emiliani, S.; Benarous, R.; Engelborghs, Y.; Christ, F.; Debyser, Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J. Biol. Chem. 2005, 280, 17841-17847.
74. Emiliani, S.; Mousnier, A.; Busschots, K.; Maroun, M.; Van Maele, B.; Tempe, D.; Vandekerckhove, L.; Moisant, F.; Ben-Slama, L.; Witvrouw, M.; J. Virol. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 2005, 280, 25517-25523.
75. Ciuffi, A.; Llano, M.; Poeschla, E.; Hoffmann, C.; Leipzig, J.; Shinn, P.; Ecker, J.R.; Bushman, F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 2005, 11, 1287-1289.
76. Gijsbers, R.; Ronen, K.; Vets, S.; Malani, N.; De Rijck, J.; McNeely, M.; Bushman, F.D.; Debyser, Z. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 2010, 18, 552-560.
77. Marshall, H.M.; Ronen, K.; Berry, C.; Llano, M.; Sutherland, H.; Saenz, D.; Bickmore, W.; Poeschla, E.; Bushman, F.D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE 2007, 2, e1340.
78. Shun, M.C.; Raghavendra, N.K.; Vandegraaff, N.; Daigle, J.E.; Hughes, S.; Kellam, P.; Cherepanov, P.; Engelman, A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Gene. Develop. 2007, 21, 1767-1778.
79. Bartholomae, C.C.; Arens, A.; Balaggan, K.S.; Yanez-Munoz, R.J.; Montini, E.; Howe, S.J.; Paruzynski, A.; Korn, B.; Appelt, J.U.; Macneil, A.; J. Virol. Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues. Mol. Ther. 2011, 19, 703-710.
80. Hendrix, J.; Gijsbers, R.; De Rijck, J.; Voet, A.; Hotta, J.; McNeely, M.; Hofkens, J.; Debyser, Z.; Engelborghs, Y. The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering. Nucl. Acid. Res. 2011, 39, 1310-1325.
81. Silvers, R.M.; Smith, J.A.; Schowalter, M.; Litwin, S.; Liang, Z.; Geary, K.; Daniel, R.Modification of integration site preferences of an HIV-1-based vector by expression of a novel synthetic protein. Hum. Gene. Ther. 2010, 21, 337-349.
82. Meehan, A.M.; Poeschla, E.M. Chromatin tethering and retroviral integration: recent discoveries and parallels with DNA viruses. Biochim. Biophys. Acta 2010, 1799, 182-191.
83. Ferris, A.L.; Wu, X.; Hughes, C.M.; Stewart, C.; Smith, S.J.; Milne, T.A.; Wang, G.G.; Shun, M.C.; Allis, C.D.; Engelman, A.; Hughes, S.H. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 3135-3140.
84. Meekings, K.N.; Leipzig, J.; Bushman, F.D.; Taylor, G.P.; Bangham, C.R. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog. 2008, 4, e1000027.
85. Derse, D.; Crise, B.; Li, Y.; Princler, G.; Lum, N.; Stewart, C.; McGrath, C.F.; Hughes, S.H.; Munroe, D.J.; Wu, X. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J. Virol. 2007, 81, 6731-6741.
86. Maxfield, L.F.; Fraize, C.D.; Coffin, J.M. Relationship between retroviral DNA-integration-site selection and host cell transcription. Proc. Nat. Acad. Sci. U. S. A. 2005, 102, 1436-1441.
87. Lewinski, M.K.; Bisgrove, D.; Shinn, P.; Chen, H.; Hoffmann, C.; Hannenhalli, S.; Verdin, E.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 2005, 79, 6610-6619.
88. Taganov, K.D.; Cuesta, I.; Daniel, R.; Cirillo, L.A.; Katz, R.A.; Zaret, K.S.; Skalka, A.M. Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. J. Virol. 2004, 78, 5848-5855.
89. Felice, B.; Cattoglio, C.; Cittaro, D.; Testa, A.; Miccio, A.; Ferrari, G.; Luzi, L.; Recchia, A.; Mavilio, F. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS ONE 2009, 4, e4571.
90. Biasco, L.; Ambrosi, A.; Pellin, D.; Bartholomae, C.; Brigida, I.; Roncarolo, M.G.; Di Serio, C.; von Kalle, C.; Schmidt, M.; Aiuti, A. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol. Med. 2011, 3, 89-101.
91. Baum, C. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials. EMBO Mol. Med. 2011, 3, 75-77.
92. Baum, C.; Dullmann, J.; Li, Z.; Fehse, B.; Meyer, J.; Williams, D.A.; von Kalle, C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101, 2099-2114.
93. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Bartholomae, C.C.; Ranzani, M.; Benedicenti, F.; Sergi, L.S.; Ambrosi, A.; Ponzoni, M.; et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 2009, 119, 964-975.
94. Maruggi, G.; Porcellini, S.; Facchini, G.; Perna, S.K.; Cattoglio, C.; Sartori, D.; Ambrosi, A.; Schambach, A.; Baum, C.; Bonini, C.; et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 2009, 17, 851-856.
95. Modlich, U.; Bohne, J.; Schmidt, M.; von Kalle, C.; Knoss, S.; Schambach, A.; Baum, C. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108, 2545-2553.
96. Lund, A.H.; Turner, G.; Trubetskoy, A.; Verhoeven, E.; Wientjens, E.; Hulsman, D.; Russell, R.; DePinho, R.A.; Lenz, J.; van Lohuizen, M. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 2002, 32, 160-165.
97. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi, L.S.; Benedicenti, F.; Ambrosi, A.; Di Serio, C. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 2006, 24, 687-696.
98. Bauer, T.R. Jr.; Allen, J.M.; Hai, M.; Tuschong, L.M.; Khan, I.F.; Olson, E.M.; Adler, R.L.; Burkholder, T.H.; Gu, Y.C.; Russell, D.W.; J. Virol. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat. Med. 2008, 14, 93-97.
99. Li, J.; Shen, H.; Himmel, K.L.; Dupuy, A.J.; Largaespada, D.A.; Nakamura, T.; Shaughnessy, J.D. Jr.; Jenkins, N.A.; Copeland, N.G. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat. Genet. 1999, 23, 348-353.
100. Pfeifer, G.P.; Steigerwald, S.D.; Mueller, P.R.; Wold, B.; Riggs, A.D. Genomic sequencing and methylation analysis by ligation mediated PCR. Science 1989, 246, 810-813.
101. Mueller, P.R.; Wold, B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 1989, 246, 780-786.
102. Silver, J.; Keerikatte, V. Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J. Virol. 1989, 63, 1924-1928.
103. Schmidt, M.; Schwarzwaelder, K.; Bartholomae, C.; Zaoui, K.; Ball, C.; Pilz, I.; Braun, S.; Glimm, H.; von Kalle, C. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods 2007, 4, 1051-1057.
104. Schmidt, M.; Hoffmann, G.; Wissler, M.; Lemke, N.; Mussig, A.; Glimm, H.; Williams, D.A.; Ragg, S.; Hesemann, C.U.; von Kalle, C. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum. Gene. Ther. 2001, 12, 743-749.
105. Schmidt, M.; Carbonaro, D.A.; Speckmann, C.; Wissler, M.; Bohnsack, J.; Elder, M.; Aronow, B. J.; Nolta, J.A.; Kohn, D.B.; von Kalle, C. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat. Med. 2003, 9, 463-468.
106. Gabriel, R.; Eckenberg, R.; Paruzynski, A.; Bartholomae, C.C.; Nowrouzi, A.; Arens, A.; Howe, S.J.; Recchia, A.; Cattoglio, C.; Wang, W.; et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 2009, 15, 1431-1436.
107. Paruzynski, A.; Arens, A.; Gabriel, R.; Bartholomae, C.C.; Scholz, S.; Wang, W.; Wolf, S.; Glimm, H.; Schmidt, M.; von Kalle, C. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protocol. 2010, 5, 1379-1395.
108. Warlich, E.; Kuehle, J.; Cantz, T.; Brugman, M.H.; Maetzig, T.; Galla, M.; Filipczyk, A.A.; Halle, S.; Klump, H.; Scholer, H.R.; et al. Lentiviral Vector Design and Imaging Approaches to Visualize the Early Stages of Cellular Reprogramming. Mol. Ther. 2011, 19, 782-789.
109. Schmidt, M.; Schwarzwaelder, K.; Bartholomae, C.C.; Glimm, H.; von Kalle, C. Detection of retroviral integration sites by linear amplification-mediated PCR and tracking of individual integration clones in different samples. Meth. Mol. Biol. 2009, 506, 363-372.
110. Cartier, N.; Hacein-Bey-Abina, S.; Bartholomae, C.C.; Veres, G.; Schmidt, M.; Kutschera, I.; Vidaud, M.; Abel, U.; Dal-Cortivo, L.; Caccavelli, L.; et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326, 818-823.
111. Schwarzwaelder, K.; Howe, S.J.; Schmidt, M.; Brugman, M.H.; Deichmann, A.; Glimm, H.; Schmidt, S.; Prinz, C.; Wissler, M.; King, D.J.; et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 2007, 117, 2241-2249.
112. Deichmann, A.; Hacein-Bey-Abina, S.; Schmidt, M.; Garrigue, A.; Brugman, M.H.; Hu, J.; Glimm, H.; Gyapay, G.; Prum, B.; Fraser, C.C.; et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 2007, 117, 2225-2232.
113. Ott, M.G.; Schmidt, M.; Schwarzwaelder, K.; Stein, S.; Siler, U.; Koehl, U.; Glimm, H.; Kuhlcke, K.; Schilz, A.; Kunkel, H.; et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401-409.
114. Boztug, K.; Schmidt, M.; Schwarzer, A.; Banerjee, P.P.; Diez, I.A.; Dewey, R.A.; Bohm, M.; Nowrouzi, A.; Ball, C.R.; Glimm, H.; et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 2010, 363, 1918-1927.
115. Wang, G.P.; Garrigue, A.; Ciuffi, A.; Ronen, K.; Leipzig, J.; Berry, C.; Lagresle-Peyrou, C.; Benjelloun, F.; Hacein-Bey-Abina, S.; Fischer, A.; et al. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucl. Acid. Res. 2008, 36, e49.
116. Wang, G.P.; Berry, C.C.; Malani, N.; Leboulch, P.; Fischer, A.; Hacein-Bey-Abina, S.; Cavazzana-Calvo, M.; Bushman, F.D. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010, 115, 4356-4366.
117. Stein, S.; Ott, M.G.; Schultze-Strasser, S.; Jauch, A.; Burwinkel, B.; Kinner, A.; Schmidt, M.; Kramer, A.; Schwable, J.; Glimm, H.; et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010, 16, 198-204.
118. Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K.; et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467, 318-322.
119. Payne, G.S.; Bishop, J.M.; Varmus, H.E. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature 1982, 295, 209-214.
120. Payne, G.S.; Courtneidge, S.A.; Crittenden, L.B.; Fadly, A.M.; Bishop, J.M.; Varmus, H.E. Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state. Cell 1981, 23, 311-322.
121. Neel, B.G.; Hayward, W.S.; Robinson, H.L.; Fang, J.; Astrin, S.M. Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion. Cell 1981, 23, 323-334.
122. Hayward, W.S.; Neel, B.G.; Astrin, S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290, 475-480.
123. Kool, J.; Berns, A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat. Rev. Canc. 2009, 9, 389-399.
124. Rosenberg, N.; Jolicoeur, P. Retroviral pathogenesis. In Retroviruses; Coffin, J.M., Hughes, S.H., Varmus, E.H. Eds.; ColdSpring Harbor Laboratory Press: Cold Spring harbor, New York, NY, USA, 1997, S475-S586.
125. Moolten, F.L.; Cupples, L.A. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene. Ther. 1992, 3, 479-486.
126. Li, Z.; Dullmann, J.; Schiedlmeier, B.; Schmidt, M.; von Kalle, C.; Meyer, J.; Forster, M.; Stocking, C.; Wahlers, A.; Frank, O.; Ostertag, W.; et al. Murine leukemia induced by retroviral gene marking. Science 2002, 296, 497.
127. Modlich, U.; Kustikova, O.S.; Schmidt, M.; Rudolph, C.; Meyer, J.; Li, Z.; Kamino, K.; von Neuhoff, N.; Schlegelberger, B.; Kuehlcke, K.; et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005, 105, 4235-4246.
128. Calmels, B.; Ferguson, C.; Laukkanen, M.O.; Adler, R.; Faulhaber, M.; Kim, H.J.; Sellers, S.; Hematti, P.; Schmidt, M.; von Kalle, C.; et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005, 106, 2530-2533.
129. Kustikova, O.; Fehse, B.; Modlich, U.; Yang, M.; Dullmann, J.; Kamino, K.; von Neuhoff, N.; Schlegelberger, B.; Li, Z.; Baum, C. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308, 1171-1174.
130. Seggewiss, R.; Pittaluga, S.; Adler, R.L.; Guenaga, F.J.; Ferguson, C.; Pilz, I.H.; Ryu, B.; Sorrentino, B.P.; Young, W.S.; Donahue, R.E.; et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006, 107, 3865-3867.
131. Aiuti, A.; Cattaneo, F.; Galimberti, S.; Benninghoff, U.; Cassani, B.; Callegaro, L.; Scaramuzza, S.; Andolfi, G.; Mirolo, M.; Brigida, I.; et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360, 447-458.
132. Woods, N.B.; Bottero, V.; Schmidt, M.; von Kalle, C.; Verma, I.M. Gene therapy: Therapeutic gene causing lymphoma. Nature 2006, 440, 1123.
133. Thrasher, A.J.; Gaspar, H.B.; Baum, C.; Modlich, U.; Schambach, A.; Candotti, F.; Otsu, M.; Sorrentino, B.; Scobie, L.; Cameron, E.; et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006, 443, E5-E6; discussion E6-E7.
134. Dave, U.P.; Akagi, K.; Tripathi, R.; Cleveland, S.M.; Thompson, M.A.; Yi, M.; Stephens, R.; Downing, J.R.; Jenkins, N.A.; Copeland, N.G. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 2009, 5, e1000491.
135. Cartier, N.; Aubourg, P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 2010, 20, 857-862.
136. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi Sergi, L.; Benedicenti, F.; Ambrosi, A.; Di Serio, C.; et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 2006, 24, 687-696.
137. Modlich, U.; Navarro, S.; Zychlinski, D.; Maetzig, T.; Knoess, S.; Brugman, M.H.; Schambach, A.; Charrier, S.; Galy, A.; Thrasher, A.J.; et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 2009, 17, 1919-1928.
138. Daya, S.; Berns, K.I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 2008, 21, 583-593.
139. Russell, D.W. AAV vectors, insertional mutagenesis, and cancer. Mol. Ther. 2007, 15, 1740-1743.
140. Donsante, A.; Miller, D.G.; Li, Y.; Vogler, C.; Brunt, E.M.; Russell, D.W.; Sands, M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317, 477.
141. Wanisch, K.; Yanez-Munoz, R.J. Integration-deficient lentiviral vectors: A slow coming of age. Mol. Ther. 2009, 17, 1316-1332.
142. Yanez-Munoz, R.J.; Balaggan, K.S.; MacNeil, A.; Howe, S.J.; Schmidt, M.; Smith, A.J.; Buch, P.; MacLaren, R.E.; Anderson, P.N.; Barker, S.E.; et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 2006, 12, 348-353.
143. Bushman, F. Targeting retroviral integration? Mol. Ther. 2002, 6, 570-571.
144. Urnov, F.D.; Rebar, E.J.; Holmes, M.C.; Zhang, H.S.; Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11, 636-646.
145. Ivics, Z.; Izsvak, Z. The expanding universe of transposon technologies for gene and cell engineering. Mob. DNA 2010, 1, 25.
146. Copeland, N.G.; Jenkins, N.A. Harnessing transposons for cancer gene discovery. Nat. Rev. Canc. 2010, 10, 696-706.
147. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872.
148. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663-676.
149. Yamanaka, S.; Blau, H.M. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010, 465, 704-712.
150. Vierbuchen, T.; Ostermeier, A.; Pang, Z.P.; Kokubu, Y.; Sudhof, T.C.; Wernig, M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463, 1035-1041.
151. Szabo, E.; Rampalli, S.; Risueno, R.M.; Schnerch, A.; Mitchell, R.; Fiebig-Comyn, A.; Levadoux-Martin, M.; Bhatia, M. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010, 468, 521-526.
152. Ieda, M.; Fu, J.D.; Delgado-Olguin, P.; Vedantham, V.; Hayashi, Y.; Bruneau, B.G.; Srivastava, D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142, 375-386.
153. Papapetrou, E.P.; Lee, G.; Malani, N.; Setty, M.; Riviere, I.; Tirunagari, L.M.; Kadota, K.; Roth, S.L.; Giardina, P.; Viale, A.; et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat. Biotechnol. 2011, 29, 73-78.
154. Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem. Cell 2007, 1, 39-49.
155. Ellis, J.; Baum, C.; Benvenisty, N.; Mostoslavsky, G.; Okano, H.; Stanford, W.L.; Porteus, M.; Sadelain, M. Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem. Cell 2010, 7, 429-430.
156. Suzuki, T.; Shen, H.; Akagi, K.; Morse, H.C.; Malley, J.D.; Naiman, D.Q.; Jenkins, N.A.; Copeland, N.G. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 2002, 32, 166-174.
157. Akagi, K.; Suzuki, T.; Stephens, R.M.; Jenkins, N.A.; Copeland, N.G. RTCGD: Retroviral tagged cancer gene database. Nucl. Acid. Res. 2004, 32, D523-D527.
158. Starr, T.K.; Allaei, R.; Silverstein, K.A.; Staggs, R.A.; Sarver, A.L.; Bergemann, T.L.; Gupta, M.; O'Sullivan, M.G.; Matise, I.; Dupuy, A.J.; et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009, 323, 1747-1750.
159. Dupuy, A.J.; Rogers, L.M.; Kim, J.; Nannapaneni, K.; Starr, T.K.; Liu, P.; Largaespada, D.A.; Scheetz, T.E.; Jenkins, N.A.; Copeland, N.G. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Canc. Res. 2009, 69, 8150-8156.
160. Du, Y.; Spence, S.E.; Jenkins, N.A.; Copeland, N.G. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 2005, 106, 2498-2505.
161. Du, Y.; Jenkins, N.A.; Copeland, N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005, 106, 3932-3939.
162. Copeland, N.G.; Jenkins, N.A. Retroviral integration in murine myeloid tumors to identify Evi-1, a novel locus encoding a zinc-finger protein. Adv. Canc. Res. 1990, 54, 141-157.
163. Neff, T.; Shotkoski, F.; Stamatoyannopoulos, G. Stem cell gene therapy, position effects and chromatin insulators. Stem Cells 1997, 15, 265-271.
164. Valenzuela, L.; Kamakaka, R.T. Chromatin insulators. Annu. Rev. Genet. 2006, 40, 107-138.
165. Arumugam, P.I.; Higashimoto, T.; Urbinati, F.; Modlich, U.; Nestheide, S.; Xia, P.; Fox, C.; Corsinotti, A.; Baum, C.; Malik, P. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol. Ther. 2009, 17, 1929-1937.